Bexsero Meningitis B Vaccine Description
Bexsero vaccine contains different proteins taken from group B Neisseria meningitidis bacteria. The combination of proteins was chosen to protect against the majority of MenB strains.
Apart from these active ingredients, the vaccine contains minimal amounts of these ingredients: Aluminium which strengthens and lengthens the immune response to the vaccine, salt (sodium chloride), sugar (sucrose), and an amino acid called histidine, both used as acidity regulators. Therefore, anyone allergic to these ingredients or who had a severe allergic reaction after a previous dose should not receive BEXSERO.
BEXSERO (Meningococcal Group B Vaccine) suspension for intramuscular injection was initially approved in the USA in 2015. The approval of BEXSERO is based on the demonstration of the immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.
Researcher Professor Finn stated on December 1, 2020, "Although rare, meningococcus group B infection can become life-threatening within hours and can cause long-term disabilities. Young children, in particular, are more at risk and may die or be seriously harmed even with top-quality hospital treatment. This important new study confirms that 4CMenB offers children a very high level of protection against suffering severe outcomes from this potentially deadly infection."
UK-based GSK is the producer of Bexsero. DrugBank Accession Number: DB10786
Bexsero Meningitis B Vaccine Indication
Bexsero is an FDA-approved vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup B. Bexsero was approved for use in 2015 for individuals 10 through 25 years of age. Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. A different meningococcal vaccine is available that can help protect against serogroups A, C, W, and Y says the U.S. CDC.
BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine or after a previous dose of BEXSERO.
Bexsero Meningitis B Vaccine Dosage
Bexsero is for intramuscular use only. The two doses of Bexsero can be completed in 1 month.
Bexsero Meningitis B Vaccine News
September 18, 2021 - The WHO reported a total of 608 suspected including 12 confirmed cases of meningitis, and 161 deaths (case fatality ratio of 26%), have been reported in the Banalia health zone of the Democratic Republic of the Congo. Among these cases, 68% are aged 15 years or older.
September 8, 2021 - The World Health Organization in Africa reported that the Democratic Republic of the Congo had declared a Neisseria meningitidis outbreak in the north-eastern Tshopo Province. About 261 suspected cases and 129 deaths have been reported.
August 26, 2021 - GlaxoSmithKline is promoting the distinction between the common MenACWY vaccine for adolescents and the separate MenB vaccine for older teens. Lending GSK's "Ask2BSure" campaign is former child actor Soleil Moon Frye, who starred in the popular '80s show "Punky Brewster."
July 28, 2021 - GSK reported financial results. Menveo sales were up 55% AER, 71% CER to £59 million, primarily driven by higher demand in the U.S., partly offset by unfavorable phasing and lower demand in International.
June 28, 2021 - The U.K. published: Freedom of Information request on a detailed report of the vaccine injuries and deaths of the Bexsero vaccine since it came out in 2016 (FOI 21-364).
December 1, 2020 - Meningococcus group B, the most prevalent strain of the meningococcal infection, is prevented with 79% effectiveness in children and young adults inoculated with the 4CMenB vaccine, also known as Bexsero, according to a new collaborative study from researchers in Portugal and the U.K. and led by the University of Bristol which evaluated the vaccine's performance in a real-world setting. This matched case-control study published by the JAMA that included 299 children, the likelihood of full vaccination with 4CMenB among children old enough to be fully immunized was significantly lower among cases with group B invasive meningococcal disease compared with controls without the invasive meningococcal disease (odds ratio, 0.21). Furthermore, 11 children with meningococcal infection who had received at least one dose of the 4CMenB vaccine survived, and none were left with related disabilities. In contrast, among the remaining 87 cases who were unvaccinated, seven died, and 16 suffered long-term injuries, suggesting that the vaccinated cases may have been partially protected. This finding means that during the first 5 years of vaccine availability in Portugal, full vaccination with 4CMenB was less likely among children who developed group B invasive meningococcal disease than matched controls.
Bexsero Meningitis B Vaccine Clinical Trials
Bexsero Meningitis B Vaccine Has been tested in over 80 clinical studies.